Cell No. : Cell Name
RCB1440 : ATN-1
update : 2022/11/08
|
| Comment | Adult T-cell leukemia. HTLV-1 pro-virus DNA(+). Based on the information by depositor; (1) this cell line possesses HTLV-1 pro-virus DNA, (2) the HTLV-1 proteins (p19, p24, p53, gp46) cannot be detected with western blotting. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
Cell line to be handled at BSL 2(C-0070.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Naoe, Tomoki
|
| Originator |
Naoe, Tomoki
|
| Year of deposit |
1998
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
47 years
|
| Tissue |
blood
|
| Classification |
cancer
|
| Year of origin |
1982
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| BSL |
BSL2
|
| Cellosaurus(Expasy) |
CVCL_1073
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Medium and additives |
|
RPMI1640 + 10% FBS + 0.1mM NEAA
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 5 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
LT 400
|
| Virus (HTLV-1) |
|
DNA (+)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
83-89(50) : /84(5),85(8),86(17),87(13),88(4),89(1)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
10
|
| User's Publication |
|
20599
Wang Y, Zheng N, Sun T, Zhao H, Chen Y, Liu C.
Role of TGM2 in T‑cell lymphoblastic lymphoma via regulation of IL‑6/JAK/STAT3 signalling.
Mol Med Rep
2022
25(3)
PubMed ID: 35014680
DOI: 10.3892/mmr.2022.12592
|
|
16945
Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.
Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy
Cancer Sci
2022
113(6):2129-2143
PubMed ID: 35343027
DOI: 10.1111/cas.15349
|
|
10693
Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka
Targeting Aberrant DNA Hypermethylation as a Driver of ATL Leukemogenesis Using the New Oral Demethylating Agent OR-2100
Blood
2020
136(7):871-884
PubMed ID: 32391874
DOI: 10.1182/blood.2019003084
|
|
10951
Yanlan Wang, Yue Liu, Changhua Zhou, Chunnian Wang, Ning Zhang, Donglin Cao, Qing Li, Zhong Wang
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
Leuk Lymphoma
2020
61(7):1660-1668
PubMed ID: 32091283
DOI: 10.1080/10428194.2020.1728746
|
|
13930
Kawamura K, Tanaka Y, Nakasone H, Ishihara Y, Kako S, Kobayashi S, Tanaka Y, Ohmori T, Uchimaru K, Okamoto S, Mineno J, Shiku H, Nishimura S, Kanda Y.
Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia
Biol Blood Marrow Transplant
2020
26(8):1377-1385
PubMed ID: 32311478
DOI: 10.1016/j.bbmt.2020.04.006
|
|
11579
Watanabe M, Sugawara A, Noguchi Y, Hirose T, Ōmura S, Sunazuka T, Horie R.
Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action.
Eur J Med Chem
2019
178:636-647
PubMed ID: 31226655
DOI: 10.1016/j.ejmech.2019.05.079
|
|
6834
Yamagishi M et al
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Cell Rep
2019
29(8):2321-2337
PubMed ID: 31747604
DOI: 10.1016/j.celrep.2019.10.083
|
|
4150
Ito T, Kasai Y, Kumagai Y, Suzuki D, Ochiai-Noguchi M, Irikura D, Miyake S, Murakami Y.
Quantitative Analysis of Interaction Between CADM1 and Its Binding Cell-Surface Proteins Using Surface Plasmon Resonance Imaging.
Front Cell Dev Biol
2018
PubMed ID: 30131958
DOI: 10.3389/fcell.2018.00086
|
|
10269
Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.
Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages
J Clin Exp Hematop
2017
57:15-20
PubMed ID: 28420814
DOI: 10.3960/jslrt.17003
|
|
9736
Horlad H, Ohnishi K, Ma C, Fujiwara Y, Niino D, Ohshima K, Jinushi M, Matsuoka M, Takeya M, Komohara Y.
TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma.
Oncol Lett
2016
12:1519-1524
PubMed ID: 27446463
DOI: 10.3892/ol.2016.4774
|
Back
Top
CELL BANK Website
